This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Talano, J.-A. M.
Right arrow Articles by Scott, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Talano, J.-A. M.
Right arrow Articles by Scott, J. P.
Related Collections
Right arrow Blood
PEDIATRICS Vol. 111 No. 6 June 2003, pp. e661-e665

ELECTRONIC ARTICLE

Delayed Hemolytic Transfusion Reaction/Hyperhemolysis Syndrome in Children With Sickle Cell Disease

Julie-An M. Talano, MD*,||, Cheryl A. Hillery, MD*,§,||, Jerome L. Gottschall, MD{ddagger},§,||, Diane M. Baylerian, BS, MT§,|| and J. Paul Scott, MD*,§,||

* Departments of Pediatrics
{ddagger} Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin
§ The Blood Center of Southeastern Wisconsin Inc, Milwaukee, Wisconsin
|| The Children’s Hospital of Wisconsin, Milwaukee, Wisconsin

Objective. Alloimmunization in patients with sickle cell disease (SCD) has a reported incidence of 5% to 36%. One complication of alloimmunization is delayed hemolytic transfusion reaction/hyperhemolysis (DHTR/H) syndrome, which has a reported incidence of 11%. In patients with SCD, clinical findings in DHTR/H syndrome occur approximately 1 week after the red blood cell (RBC) transfusion and include the onset of increased hemolysis associated with pain and profound anemia. The hemoglobin (Hb) often drops below pretransfusion levels. In many reported adult cases, the direct antiglobulin test (DAT) remains negative and no new alloantibody is detected as the cause for these transfusion reactions. To date, few pediatric cases have been reported with this phenomenon. The objective of this study was to describe the clinical and laboratory findings of a case series in children who had SCD and experienced a DHTR/H syndrome at our institution.

Methods. An 11-year retrospective chart review of patients with discharge diagnosis of SCD and transfusion reaction was performed. DHTR/H syndrome was defined as the abrupt onset of signs and symptoms of accelerated hemolysis evidenced by an unexplained fall in Hb, elevated lactic dehydrogenase, elevated bilirubin above baseline, and hemoglobinuria, all occurring between 4 and 10 days after an RBC transfusion. Patient characteristics, time from transfusion, symptoms, reported DAT, new autoantibody or alloantibody formation, laboratory abnormalities, and complications were recorded. Patients with acute transfusion reactions were excluded.

Results. We encountered 7 patients who developed 9 episodes of DHTR/H syndrome occurring 6 to 10 days after RBC transfusion. Each presented with fever and hemoglobinuria. All but 1 patient experienced pain initially ascribed to vaso-occlusive crisis. The DAT was positive in only 2 of the 9 episodes. The presenting Hb was lower than pretransfusion levels in 8 of the 9 events. Severe complications were observed after the onset of DHTR/H: acute chest syndrome, n = 3; pancreatitis, n = 1; congestive heart failure, n = 1; and acute renal failure, n = 1.

Conclusions. DHTR/H syndrome occurs in pediatric SCD patients, typically 1 week posttransfusion, and presents with back, leg, or abdominal pain; fever; and hemoglobinuria that may mimic pain crisis. Hb is often lower than it was at the time of original transfusion, suggesting the hemolysis of the patient’s own RBCs in addition to hemolysis of the transfused RBCs; a negative DAT and reticulocytopenia are often present. Severe complications including acute chest syndrome, congestive heart failure, pancreatitis, and acute renal failure were associated with DHTR/H syndrome in our patients. DHTR/H in the pediatric sickle cell population is a serious and potentially life-threatening complication of RBC transfusion. It is important to avoid additional transfusions in these patients, if possible, because these may exacerbate the hemolysis and worsen the degree of anemia. DHTR/H syndrome must be included in the differential of a patient who has SCD and vaso-occlusive crisis who has recently had a transfusion.

Key Words: delayed hemolytic transfusion reaction/hyperhemolysis • sickle cell disease

Abbreviations: SCD, sickle cell disease • RBC, red blood cell • DHTR/H, delayed hemolytic transfusion reaction/hyperhemolysis • Hb, hemoglobin • DAT, direct antiglobulin test • IVIg, intravenous immunoglobulin

Received for publication Oct 15, 2002; Accepted Feb 19, 2003.




This article has been cited by other articles:


Home page
 haematolHome page
F. Noizat-Pirenne, D. Bachir, P. Chadebech, M. Michel, A. Plonquet, J.-C. Lecron, F. Galacteros, and P. Bierling
Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease
Haematologica, December 1, 2007; 92(12): e132 - e135.
[Abstract] [Full Text] [PDF]